Characteristics of second primary malignancies following bispecific antibodies therapy
Our study provides the first detailed characterization of SPMs post-BsAb, underscoring the need for continued pharmacovigilance and individualized risk management to mitigate SPM risks in patients undergoing BsAb therapy.
Authors
- Xinyu Zhou (ORCID: https://orcid.org/0009-0004-5342-4664)
- Keren Chen (ORCID: https://orcid.org/0000-0002-2386-3541)
- Hongsheng Zhou (ORCID: https://orcid.org/0000-0002-4888-7021)
- Liang Wang (ORCID: https://orcid.org/0000-0001-6140-914X)
- Jia Guo
- Dan Liu (ORCID: https://orcid.org/0009-0004-0858-0561)
- Xiaojie Liang (ORCID: https://orcid.org/0000-0003-4135-3155)
- Weixiang Lu
- Baiwei Luo (ORCID: https://orcid.org/0000-0002-0374-5724)
- B.Y. Lin
- Zihong Cai (ORCID: https://orcid.org/0009-0005-4848-9508)
- Zhengming Jin
- Shengyu Tian
- Tong Li (ORCID: https://orcid.org/0009-0009-6087-669X)
Institutions
- Beijing Tongren Hospital (CN)
- Guangdong Medical College (CN)
- Capital Medical University (CN)
- The First People's Hospital of Shunde (CN)
- Nanfang Hospital (CN)
- Boxing People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-011200
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- National Natural Science Foundation of China